{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:05:21Z","timestamp":1790697921809,"version":"4.1.0"},"reference-count":29,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of VitreoRetinal Diseases"],"abstract":"<jats:p>\n                    <jats:bold>Purpose:<\/jats:bold>\n                    To characterize antivascular endothelial growth factor medication transitions among patients with neovascular age-related macular degeneration (nAMD), including delays in care and economic impacts.\n                    <jats:bold>Methods:<\/jats:bold>\n                    A retrospective observational cohort study analyzed participants with nAMD in the IRIS (Intelligent Research in Sight) Registry who were treated with antivascular endothelial growth factor agents from 2015 to 2024. Four cohorts were analyzed: (1) bevacizumab only, (2) bevacizumab transitioned to a biosimilar, (3) bevacizumab transitioned to a branded agent, and (4) bevacizumab transitioned to a biosimilar and then to a branded agent. The main outcome measures were number of intravitreal injection events, transitions in medications, and injection intervals.\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of 182 757 eyes with nAMD met inclusion criteria: 136 451 received bevacizumab only; 2184, bevacizumab followed by a biosimilar; 335, bevacizumab followed by a biosimilar, followed by branded medication; and 43 787, bevacizumab followed by a branded agent. Newer agents (faricimab and aflibercept 8 mg) experienced additional delays of 8.6 days compared with aflibercept 2 mg (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; .001). Economic modeling based on IRIS transition rates and medication cost showed that bevacizumab transitioned to a biosimilar and then to a branded agent was 36.3% and 11.62% more costly than bevacizumab transitioned to a biosimilar (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; .001) and bevacizumab transitioned to a branded agent (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; .001), respectively, within 2 years. Similar cost differences persisted in 5- and 10-year projections. Bevacizumab transitioned to a biosimilar and then to a branded agent was the costliest pathway compared with transitions to biosimilars and branded agents, regardless of which branded agent was used.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    IRIS Registry cohort data suggest possible demographic differences in patients undergoing medication transitions, including biosimilar agents, as well as delays in care with medication transitions. Economic simulations suggest that multiple transitions may be more costly than direct transitions from bevacizumab to either biosimilar or branded agents.\n                  <\/jats:p>","DOI":"10.1177\/24741264261455206","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:32:31Z","timestamp":1781872351000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Intravitreal Anti-VEGF Injection Transitions Across Bevacizumab, Biosimilar, and Branded Medications: The IRIS Registry Study"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-7192","authenticated-orcid":false,"given":"Sean T.","family":"Berkowitz","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua B.","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor J.","family":"Ross","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Kearney","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Lorch","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan W.","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Rossin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Paul","family":"Sternberg","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avni P.","family":"Finn","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2017.12.006"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102673"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.04.008"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.5403"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.04.019"},{"key":"e_1_3_2_7_2","article-title":"Step therapy: clinicians\u2019 concerns and challenges. Online","author":"Mott M.","year":"2022","unstructured":"Mott M. Step therapy: clinicians\u2019 concerns and challenges. Online: EyeNet Magazine, 2022; v. 2024.","journal-title":"EyeNet Magazine"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2021.00822"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.2217"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204225"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2022.11.010"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-022-00453-7"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100421"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.02.021"},{"key":"e_1_3_2_15_2","unstructured":"IBM Micromedex RED BOOK Online. IBM Watson Health; 2022. Accessed December 2024. https:\/\/www.micromedexsolutions.com"},{"key":"e_1_3_2_16_2","unstructured":"Centers for Medicare & Medicaid Services DoHaHS. July 2024 ASP Pricing File. 2024."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.38182"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.10753"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2024.100542"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/1527154415603358"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2025.100933"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2021.10.008"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.03.045"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05359-x"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2020.05.029"},{"key":"e_1_3_2_26_2","unstructured":"Drug Approval Package Eylea (Aflibercept) Injection. 11\/18\/2011; v. 11.4.2025."},{"key":"e_1_3_2_27_2","unstructured":"BYOOVIZ (ranibizumab-nuna) injection for intravitreal use [prescribing information]. Biogen; 2021. Accessed December 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761202s016lbl.pdf"},{"key":"e_1_3_2_28_2","unstructured":"CIMERLI (ranibizumab-eqrn) injection for intravitreal use [prescribing information]. Coherus BioSciences; 2022. Accessed December 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761165s005lbl.pdf"},{"key":"e_1_3_2_29_2","unstructured":"VABYSMO (faricimab-svoa) injection for intravitreal use [prescribing information]. Genentech Inc; 2022. Accessed December 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761235s000lbl.pdf"},{"key":"e_1_3_2_30_2","unstructured":"EYLEA HD (aflibercept) injection for intravitreal use [prescribing information]. Regeneron Pharmaceuticals Inc; 2023. Accessed December 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125387s087lbl.pdf"}],"container-title":["Journal of VitreoRetinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264261455206","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24741264261455206","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264261455206","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:25:53Z","timestamp":1790695553000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24741264261455206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":29,"alternative-id":["10.1177\/24741264261455206"],"URL":"https:\/\/doi.org\/10.1177\/24741264261455206","relation":{},"ISSN":["2474-1264","2474-1272"],"issn-type":[{"value":"2474-1264","type":"print"},{"value":"2474-1272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"article-number":"24741264261455206"}}